english.prescrire.org > Spotlight > Archives : 2026 > Cabergoline: fibrotic disorders and heart valve disease

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Cabergoline: fibrotic disorders and heart valve disease

 Adverse effects  Quinagolide, a non-ergot dopamine agonist used in hyperprolactinaemia, has been withdrawn from the market in several European countries. This will probably lead to an increase in the number of patients exposed to the ergot-derived dopamine agonists bromocriptine and cabergoline. 
Full article available for download by subscribers

 ©Prescrire 1 January 2026

Source: "Cabergoline: fibrotic disorders and heart valve disease" Prescrire Int 2026; 35 (277): 23. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Cabergoline
in hyperprolactinaemia:
valvulopathy"
Prescrire Int 2021;
30 (226): 124.
Subscribers only